In vivo, complex modifications involving interorgan communication create broad heterogeneity in the endocrine pancreatic response to GCs depending on the model, dose, and duration of GC treatment
A wound-healing-related gene set, described by Chang et al
Standard ENT management typically focuses on hearing protection, sound masking devices, and cognitive behavioural therapy
A Phase I safety study and a Phase II ulcerative colitis trial of the BPC-157 formulation PL 14736 were conducted by the Croatian pharmaceutical company Pliva, but full peer-reviewed Phase II efficacy results have not been published
For example, the recommended doses can vary from 500 mg to 2000 mg per day, considering factors such as how it is administered and individual health needs